Zymeron
Zymeron is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative healthcare technologies that deliver step-change performance. The company focuses on proactive health solutions to address critical unmet needs in the pharmaceutical sciences, particularly in drug delivery and formulation technologies.
Zymeron
400 Park Offices Drive, STE 211 PO Box 12072 Research Triangle Park, NC 27709
What We Do
Zymeron develops advanced drug delivery and formulation technologies to address unmet clinical needs, including a proprietary peptide drug conjugate for bone marrow drug delivery and systems for reformulating poorly soluble drugs into injectables.
Zymeron has developed the μFAST method, a rapid microbiological testing technology that provides results in under 30 minutes, enhancing quality control in biomanufacturing.
MyeloShield is a transformative solution designed to prevent chemotherapy-induced myelosuppression, protecting healthy cells during chemotherapy treatments through a proprietary peptide drug conjugate technology.
Digital Health Technologies
Application Area
Show More (1)Drugs
Vaccines
Biologics
Key People
Not specified
Not specified
News & Updates
Zymeron Corporation announced that its myelotoxicity drug program is boosted by a $3.0M federal funding to advance its lead drug candidate in preclinical studies.
Zymeron Corporation announced that it received multi-year funding from the Department of Defense to continue its development of a long-lasting antimalaria prophylactic drug.
Zymeron Corporation announced that it has relocated to the Frontier Campus Building 400, Research Triangle Park, NC, providing renovated dynamic laboratory spaces for startups.